vTv Therapeutics (VTVT) Expected to Announce Earnings on Wednesday

vTv Therapeutics (NASDAQ:VTVT) is expected to be releasing its results before the market opens on Wednesday, May 13th. Analysts expect vTv Therapeutics to post earnings of $0.21 per share and revenue of $20.00 million for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.51. On average, analysts expect vTv Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

vTv Therapeutics Price Performance

NASDAQ:VTVT opened at $30.68 on Monday. The stock has a market cap of $120.88 million, a P/E ratio of -9.16 and a beta of 0.26. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00. The company has a fifty day moving average price of $36.42 and a 200 day moving average price of $33.66.

Institutional Investors Weigh In On vTv Therapeutics

A number of hedge funds have recently made changes to their positions in VTVT. Geode Capital Management LLC increased its position in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics during the 4th quarter worth about $221,000. Finally, 683 Capital Management LLC bought a new stake in vTv Therapeutics during the 4th quarter worth about $731,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on VTVT. Evercore began coverage on shares of vTv Therapeutics in a research note on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price for the company. BTIG Research restated a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Friday, March 27th. Roth Mkm started coverage on shares of vTv Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price objective for the company. Finally, Wall Street Zen upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, vTv Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.